| 1 |
32248251 | Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma. | 2020 May |
1 |
| 2 |
32278674 | Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. | 2020 Jul |
2 |
| 3 |
31046214 | Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment | 2019 May 3 |
1 |
| 4 |
29574618 | Safety and comfort of domestic bortezomib injection in real-life experience. | 2018 Sep |
1 |
| 5 |
31620574 | Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen. | 2018 Jun |
1 |
| 6 |
28402945 | A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. | 2017 Jun 6 |
1 |
| 7 |
28906482 | Real‑life experience with bortezomib‑based regimens in elderly patients with newly diagnosed multiple myeloma and comorbidities: a Polish retrospective multicenter study. | 2017 Nov 30 |
1 |
| 8 |
26500339 | Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. | 2016 Jan 28 |
1 |
| 9 |
26671239 | First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany. | 2016 Mar |
1 |
| 10 |
27181540 | Light Chain Deposition Disease in an Older Adult Patient Successfully Treated with Long-term Administration of Bortezomib, Melphalan and Prednisone. | 2016 |
1 |
| 11 |
25684797 | Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma. | 2015 Jan |
1 |
| 12 |
24849305 | [Clincal features and treatment of multiple myeloma]. | 2014 Jun |
1 |
| 13 |
21295387 | Management of older patients with multiple myeloma. | 2011 Mar |
1 |
| 14 |
21497966 | Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? | 2011 Jul |
1 |
| 15 |
19733251 | "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. | 2010 Jan |
1 |
| 16 |
19858394 | VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. | 2009 Dec 20 |
1 |